BNP as marker of heart dysfunction in patients with liver cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 11, 2010, Pages 1331-1336

  Padillo, Javier ^a,i   Rioja, Pilar ^b   Muñoz Villanueva, María C ^d   Vallejo, Juan A ^c   Ciria, Rubén ^b   Muntane, Jordi ^e,i   Sitges Serra, Antonio ^g,i   Solórzano, Guillermo ^h   De La Mata, Manuel ^f,i  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b University Department of Surgery Austin Campus   (Australia)

^c Departments of Nuclear Medicine   (Australia)

^d Unit of Support to the Research   (Australia)

^e Liver Research Unit

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL INFANTA CRISTINA   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

BNP; cardiac function; cirrhosis; preoperative assessment

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HEART DISEASE; HEART EJECTION FRACTION; HUMAN; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; BLOOD PRESSURE; DOBUTAMINE; FEMALE; HEART DISEASES; HEART RATE; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIONUCLIDE VENTRICULOGRAPHY; SEVERITY OF ILLNESS INDEX; SPAIN; STROKE VOLUME;

EID: 78049234714     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32833e6b2a     Document Type: Article

References (27)

1. Möller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008; 57:268.
2. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42:439.
3. Pozzi M, Carugo S, Boari G., Pecci V, De Ceglia S, Maggiolini S, et al Evidence of functional and structural cardiac abnormalities in cirrhosis. Hepatology 1997; 26:1131.
4. Pozzi M, Ratti L, Redaelli E., Guidi C, Mancia G. Cardiovascular abnormalities in special conditions of advanced cirrhosis. The circulatory adaptative changes to specific therapeutic procedures for the management of refractory ascites. Gastroenterol Hepatol 2006; 29:263.
5. Marshall RI, Berger HJ, Costin J.C., Freedman GS, Wolberg J, Cohen LS Assessment of cardiac performance with quantitative radionuclide angiocardiography: sequential left-ventricular ejection fraction, normalised left ventricular ejection rate and regional wall motion. Circulation 1977; 56:820.
6. Richards MA, Crozier IG, Yandle T.G., Espiner EA, Ikram H, Nicholls MG Brain natriuretic factor: regional plasma concentrations and correlation with haemodynamic state in cardiac disease. Br Heart J 1993; 69:414.
7. Wei CM, Heublein DM, Perella M.A., Lerman A., Rodeheffer RJ, McGregor C, et al Natriuretic peptide system in human heart failure. Circulation 1993; 88:1004.
8. Marumo F, Katoh Y, Kurosawa T., Takeda S, Kurokawa S, Sakamoto H., et al. High plasma concentration of the atrial natriuretic peptide (ANP) with suppressed aldosterone secretion in congestive heart failure. Am J Cardiol 1988; 61:498.
9. Mathisen P, Hall C, Simonsen S. Comparative studies of atrial peptides ANP (1-98) and ANP (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scan J Clin Lab Invest 1993; 53:41.
10. Davis KM, Fish LC, Elahi D, Clark B.A., Minaker KL Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. JAMA 1992; 267:2625.
11. Cazzaniga M, Salerno F, Pagnozzi G., Dionigi E, Visentin S, Cirello I., et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007; 56:869.
12. Ratti L, Redaelli E, Guidi C., Rivera R, Wong F, Pozzi M. Diastolic dysfunction in liver cirrhosis. Gastroenterol Hepatol 2005; 28:649.
13. Baldus WP, Feichter RN, Summerskill WH The kidney in cirrhosis. Clinical and biochemical features of azotemia in hepatic failure. Ann Int Med 1964; 60:326.
14. Gines P, Arroyo V, Rodés J. Treatment of ascites and renal failure in cirrosis. In: Davis M, ed. Therapy of liver diseases, Bailliere's Clinical Gastroenterology. London: WB Saunders Co.; 1989, p. 165.
15. Hoffmann WP, Radle J, Moench C., Bechstein W, Zeuzem S. Prediction of perioperative mortality in patients with advanced liver disease and abdominal surgery by the use of different scoring systems and tests. Z F Gastroenterol 2008; 46:1283.
16. Ripoll C, Catalina MV, Yotti R, Olmedilla L., Pérez-Peña J, Lo Iacono O, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation 2008; 85:1766.
17. Torregrosa M, Aguadé S, Dos L, Segura R, González A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42:68.
18. Wong F, Lin P, Lilly L., Bonzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci 1999; 97:259.
19. Folland ED, Parisi AF, Moynihan P.F., Jones DR, Feldman CL, Tow DE Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiology. Circulation 1979; 60:760.
20. Donovan CL, Marcovitz PA, Punch J.D., Bach DS, Brown KA, Ucey MR, et al Two-dimensional and dobutamine stress cardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996; 61:1180.
21. Francis GS, Benedict C, Johnstone D.E., Kirlin PC, Nicklas J, Liang CS, et al Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724.
22. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left-ventricular ejection fractions. N Engl J Med 1992; 327:685.
23. Henriksen JH, Gotze JP, Fuglsang S, Christensen F., Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52:1511.
24. Salo J, Jimenez W, Kuhn M., Gines A, Gines P. Urinary excretion of urodilatin in patients with cirrhosis. Hepatology 1996; 24:1428.
25. Bates ER, Shenker J, Grekin RJ The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. Circulation 1986; 73:1155.
26. Yamaji T, Ishibashi M, Takaku F. Atrial natriuretic factor in human blood. J Clin Invest 1985; 76:1705.
27. Acosta F. Cardiologic evaluation of the candidate for liver transplantation. Transplantology 1996; 7:10.